Development and Validation of Clinically Useful Gene Signatures
September 3, 2010
IDDI organized its second free live webinar on DEVELOPMENT AND VALIDATION OF CLINICALLY USEFUL GENE SIGNATURES.
- This webinar reviewed statistical issues in the development and validation of gene signatures for breast cancer. Using three recently developed signatures (MammaPrint®, Oncotype DX® and MapQuant DxTM), the speakers discussed the role of gene selection, classification methods and cluster analysis in signature development, as well as the need for internal and external validation of the signatures.
- The speakers were Dr Marc Buyse, Chairman IDDI and Dr. Stefan Michiels, Breast Cancer Translational Unit, Institut Jules Bordet and Senior Biostatistical Consultant IDDI.
TO ACCESS THE PRESENTATION OF THIS ON-DEMAND WEBINAR, PLEASE FILL IN THE FORM BELOW